CRISPR-edited immune cells, CLR 131 in pediatric cancers and men's health
JULY 30, 2021

The use of CLR 131 and other targeted radiotherapeutics in pediatric cancers

with  Dr. Mario Otto and Dr. Daniel Morgenstern  
July 12, 2021, 1 PM EST

Many pediatric cancers have very poor overall survival rates once they relapse or if they do not respond to initial standard treatments. Radiotherapy plays an important role in the treatment of these cancers. However, if the cancer has metastasized to many sites, external beam radiotherapy becomes impracticable and too harmful to healthy body tissues. CLR 131 by Cellectar Biosciences, is a radio iodinated therapeutic that selectively delivers radiation to malignant tumor cells, thus minimizing radiation exposure to normal tissues. It consists of a cancer-targeted small-molecule compound radiolabeled with isotope iodine-131. CLR 131 has demonstrated tumor selective uptake and therapeutic efficacy in various pediatric cancers. We talked to Dr. Mario Otto, University of Wisconsin School of Medicine and Public Health and Dr. Daniel Morgenstern, SickKids about use of CLR 131 in pediatric cancers, status on the clinical trials and scope of targeted radiotherapeutics in pediatric cancers.  


Dr. Mario Otto
Dr. Daniel Morgenstern
Jeremy Pivor
Mark Unger
Shweta Mishra 
Jun 29, 2021, 10:00 am EST
The Nobel prize winning CRISPR-Cas9 genome editing system is being explored for its potential use in cancer research and treatment. By deleting, inactivating, or otherwise modifying specific genes in cultured cells or in animal models, researchers have been able to study the role of these genes in cancer development and progression, providing insight into how to prevent or treat certain cancers. The research team at University of Pennsylvania have been using CRISPR editing to improve the effectiveness of gene therapies for cancer. The latest preliminary data from their study show that removing genes known to stifle T cell activation on CAR T cells enhanced the engineered T cells’s ability to eliminate blood cancers. CureTalks panel talks to Dr. Edward A. Stadtmauer from University of Pennsylvania about CRISPR-Cas9 gene editing system and scope of the tool in cancer treatment and management.

Dr. Edward A. Stadtmauer
Matt Goldman
Jennifer Zarou
Maddie Hunter
Priya Menon
June 24, 2021, 6:00 PM EST
Several reports about the consistently declining male fertility by environmental and reproductive epidemiologists have been worrisome for scientists as well as the men’s health community. Some even claim that such decline may jeopardize the future of the human race and warrant urgent action. June was men’s health awareness month, and we are talked to the President of the Florida Urological Society, Dr Jamin Brahmbhatt – a board certified urologic surgeon specializing in chronic testicular pain and infertility – to understand the real picture behind declining sperm counts, the effect of COVID19, obesity and various kinds of stress on sperms, its implications on care for men and the proposed solutions, if any. On the patient panel are men’s health advocate David Stanley and fertility coach Kristen Darcy.

Dr. Jamin Brahmbhatt
David Stanley
Kristen Darcy
Shweta Mishra
Subscribe to CureTalks YouTube channel here.
Our Picks
TrialX Editor